Spinal Muscular Atrophy in the Age of Gene Therapy
- 15 March 2020
- journal article
- editorial
- Published by AACN Publishing in AACN Advanced Critical Care
- Vol. 31 (1), 86-91
- https://doi.org/10.4037/aacnacc2020436
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular AtrophyThe New England Journal of Medicine, 2017
- Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature reviewOrphanet Journal of Rare Diseases, 2017
- Emerging therapies and challenges in spinal muscular atrophyAnnals of Neurology, 2017
- Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation studyThe Lancet, 2016
- 480. Gene Therapy for Spinal Muscular Atrophy Type 1 Shows Potential to Improve Survival and Motor Functional OutcomesMolecular Therapy, 2016
- Spinal muscular atrophy: Diagnosis and management in a new therapeutic eraMuscle & Nerve, 2014
- Observational study of spinal muscular atrophy type I and implications for clinical trialsNeurology, 2014
- Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72 400 specimensEuropean Journal of Human Genetics, 2011
- The changing natural history of spinal muscular atrophy type 1Neurology, 2007
- Natural history of denervation in SMA: Relation to age, SMN2 copy number, and functionAnnals of Neurology, 2005